Cell & Gene Collective

12 Mar Cell & Gene Collective

Posted at 12:16h in Experience by

The Cell & Gene Collective was set up by OVID Health in 2020. It is an alliance of eight biopharmaceutical companies who wish to support the NHS and policymakers in delivering appropriately assessed, commissioned, and delivered cell and gene therapies to patients (including oncology patients).

As well as making a distinctive case for access reform for these advanced therapies, the Collective raises awareness among politicians and policy influencers on the promise of CGTs and the patient voice on this topic.

The Cell & Gene Collective’s membership is comprised of: Astellas, Bayer, BioMarin,  Johnson & Johnson, Kite (a Gilead company), Pfizer Ltd, Roche, and Vertex Pharmaceuticals.

 



Case Studies

We partnered with Roche, Macular Society and Fight for Sight to form ‘The Eyes Have It’ partnership. The partnership set out with a specific goal: to build new advocates for

We supported Sanofi UK to develop and deliver their patient advocacy strategy. This involved strengthening Sanofi’s relationships with patient groups, helping patient groups to build their capability on policy issues

The Cell & Gene Collective was set up by OVID Health in 2020. It is an alliance of eight biopharmaceutical companies who wish to support the NHS and policymakers in

Our award-nominated ‘Educating Eve’ integrated campaign supplied advice for women on gynaecological cancers. Using YouGov results from an exclusive poll we gained exceptional national media coverage across broadcast and print,

We raised this health tech company's profile and built corporate value to attract US investors as it prepared for upcoming capital raises. Our support included developing a high-impact corporate narrative

We lead MedCity’s external affairs strategy, calling for ongoing investment in London’s global life sciences powerhouse, underpinned by a media relations, high-level stakeholder engagement programme and influencing support. We have